ESSEX BIO-TECHNOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.25 HKD | 0.00% |
|
+0.45% | -9.64% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.64% | 163M | |
| -5.13% | 85.08B | |
| +2.11% | 40.14B | |
| -25.74% | 28.37B | |
| +51.96% | 24.07B | |
| -6.17% | 17.24B | |
| -31.09% | 13.85B | |
| -6.58% | 12.29B | |
| -16.04% | 11.95B | |
| -4.19% | 8.02B |
- Stock Market
- Equities
- 1061 Stock
- News Essex Bio-Technology Limited
- Essex Bio-Technology Expects 35% Fall in 2022 Profit; Shares Slip 3%
